The “Anti-fungal Drugs Market” report covers the overview of the market and presents the information on business development, market size, and share scenario. The report also emphasizes on the growth prospects of the global Anti-fungal Drugs market for the period 2020-2024. The report covers market characteristics for each segmentation across the key regions and country and traces the historic and forecast analysis of the industry. The report covers key vendors their revenue, breakdown by regions, and product demand. Other key details include volume, installed capacity, value chain.
Scope of the Report:
As per the scope of this report, anti-fungal drugs refer to the drugs used/prescribed for the treatment of diseases caused by fungi. The report covers (but is not limited to) drugs used/prescribed in aspergillosis, dermatophytosis, and candidiasis. The types of drugs covered (but are not limited to) in this report are echinocandins, azoles, polyenes, and allylamines. The definitions for individual segments have been provided in the respective segments.
For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14099134
Key Market Trends:
Azoles Segment under Drug Type Segmentation is expected to be the Fastest Growing Market over the Forecast Period
Anti-fungal drug research is gaining momentum, owing to the development of new antifungal drugs using the azole group. Azoles are synthetic and semi-synthetic compounds, widely used for superficial and invasive fungal infections. The drugs are used to treat thrush, yeast infection, candidiasis, aspergillosis, tinea versicolor, athlete’s foot, jock itch, ringworm, nail fungus, fungal infections, systemic mycosis, and seborrheic dermatitis. The azole anti-fungal group includes two classes, namely the triazoles (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) and the imidazoles (ketoconazole). Triazoles have a broad range of applications in the treatment of superficial and systemic fungal infections. The azole group offers a broad spectrum of activity and improved safety levels. The drugs have fewer adverse effects, less serious drug interactions, and improved absorption and distribution properties. The aforementioned benefits of azoles have contributed toward their dominance over other segments. The azoles are currently the most widely used and studied class of antifungal agents. The drugs are available in different formulations (oral tablet, oral capsule, cream, dandruff shampoo, sterile IV solution, lotion, vaginal cream, and tablet). The advancements and innovations in such potential drugs fuel the competitiveness of the pharmaceutical market. Sales of both the established agents and newly launched anti-fungal agents are significant. The issue with antifungal drug resistance has prompted further investigations of the underlying molecular mechanisms. Increased resistance is being observed amongst the Candida and Aspergillus species, particularly to azoles, which is believed to be driven by the use of azoles in agriculture. Increasing drug resistance is anticipated to provide an opportunity for other drug classes to capture the market.
North America is expected to account for the Largest Market Share in the Global Market
Fungal diseases in the United States have presented challenges to the healthcare authorities in the country. People across the world, including in the United States, have developed resistance to the available medicines. According to the Centers for Disease Control and Prevention (CDC), resistance to certain types of Candida (which happens to be the most common cause of healthcare-associated bloodstream infections in the United States) has been noticed. Approximately 7% of all the Candida bloodstream isolates tested at CDC are resistant to fluconazole. This observation has remained fairly constant over the last two decades. However, echinocandin resistance has been on the rise. In addition, the incidences of multi-drug resistance have increased in the country. Moreover, thirteen cases of Candida auris (which can cause invasive infections and is resistant to anti-fungal drugs) have been identified in the United States. According to the CDC, out of the thirteen, seven of the cases occurred between May 2013 and August 2016. The immunocompromised, aged population is on the rise in the United States. There were close to 46 million people aged 65 years and above in 2015. The population is expected to double (over 98 million) by 2060. This will represent about 24% of the total population in the country. This population is more susceptible to chronic diseases, such as cancer, thereby compromising the immune system. Thus, the population would be more susceptible to other diseases, like fungal diseases. The increasing incidences of resistance and immunocompromised population have been a major concern for the government. This provides an opportunity for pharmaceutical players in the country to develop novel and more effective drugs for fungal diseases.
The report provides key statistics on the market status of the Anti-fungal Drugs Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Anti-fungal Drugs.
Purchase this Report (Price 4250 USD for a single-user license) – https://www.industryresearch.co/purchase/14099134
Key Insights of Anti-fungal Drugs Market:
- Complete in-depth analysis of the Anti-fungal Drugs
- Important changes in market dynamics.
- Segmentation analysis of the market.
- Emerging segments and regional markets.
- Historical, on-going, and projected market analysis based on volume and esteem.
- Assessment of niche industry players.
- Market share analysis.
- Key strategies of major players
Anti-fungal Drugs Market Report Covers Following Points in TOC:
- Chapter 1: Anti-fungal Drugs Market Definition
- Chapter 2: Research Methodology of Anti-fungal Drugs Market
- Chapter 3: Anti-fungal Drugs Market Executive Summary
- Chapter 4: Anti-fungal Drugs Market Overview Includes Current Market Scenario, Porter’s Five Forces Analysis, Bargaining Power of Suppliers and Consumers, Threat of New Entrants and Substitute Product and Services
- Chapter 5: Market Dynamics Covers Drivers, Restraints, Opportunities and Challenges
- Chapter 6: Anti-fungal Drugs Market Segmentation by Types, End-User, and Applications Forecast to 2024
- Chapter 7: Anti-fungal Drugs Market Segmentation by Geographical Regions
- Chapter 8: Competitive Landscape of Anti-fungal Drugs Market Includes Mergers & Acquisition Analysis, Agreements, Collaborations, and Partnerships, New Products Launches
- Chapter 9: Key Players for Anti-fungal Drugs Market
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports: